187 related articles for article (PubMed ID: 34018260)
1. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
[No Abstract] [Full Text] [Related]
2. [Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report].
Wang L; Li X; He YZ
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):482. PubMed ID: 32654461
[No Abstract] [Full Text] [Related]
3. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.
El-Galaly TC; Cheah CY; Bendtsen MD; Nowakowski GS; Kansara R; Savage KJ; Connors JM; Sehn LH; Goldschmidt N; Shaulov A; Farooq U; Link BK; Ferreri AJM; Calimeri T; Cecchetti C; Dann EJ; Thompson CA; Inbar T; Maurer MJ; Gade IL; Juul MB; Hansen JW; Holmberg S; Larsen TS; Cordua S; Mikhaeel NG; Hutchings M; Seymour JF; Clausen MR; Smith D; Opat S; Gilbertson M; Thanarajasingam G; Villa D
Eur J Cancer; 2018 Apr; 93():57-68. PubMed ID: 29477102
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
T Low J; B Peters K
CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
[TBL] [Abstract][Full Text] [Related]
5. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma.
Gregory G; Arumugaswamy A; Leung T; Chan KL; Abikhair M; Tam C; Bajel A; Cher L; Grigg A; Ritchie D; Opat S
Neuro Oncol; 2013 Aug; 15(8):1068-73. PubMed ID: 23502429
[TBL] [Abstract][Full Text] [Related]
6. Rituximab-Lenalidomide-Ibrutinib Combination for Relapsed/Refractory Primary CNS Lymphoma: A Case Series of the LOC Network.
Houillier C; Chabrot CM; Moles-Moreau MP; Willems L; Ahle G; Waultier-Rascalou A; Fornecker LM; Hoang-Xuan K; Soussain C
Neurology; 2021 Sep; 97(13):628-631. PubMed ID: 34580183
[TBL] [Abstract][Full Text] [Related]
7. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
[TBL] [Abstract][Full Text] [Related]
9. O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.
Adachi J; Mishima K; Wakiya K; Suzuki T; Fukuoka K; Yanagisawa T; Matsutani M; Sasaki A; Nishikawa R
J Neurooncol; 2012 Mar; 107(1):147-53. PubMed ID: 21968944
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
Lewis KL; Chin CK; Manos K; Casey J; Hamad N; Crawford J; Ho SJ; Issa S; Grigg A; Wood P; Gandhi MK; Do B; Nastoupil L; Hawkes EA; Cheah CY
Br J Haematol; 2021 Mar; 192(6):1049-1053. PubMed ID: 32677095
[TBL] [Abstract][Full Text] [Related]
11. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
Lauer EM; Waterhouse M; Braig M; Mutter J; Bleul S; Duque-Afonso J; Duyster J; Marks R; Reinacher PC; Prinz M; Illerhaus G; Finke J; Schorb E; Scherer F
Br J Haematol; 2020 Jul; 190(2):e110-e114. PubMed ID: 32452526
[No Abstract] [Full Text] [Related]
13. Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.
Patrij K; Reiser M; Wätzel L; Pels H; Kowoll A; Herrlinger U; Engert A; Linnebank M; Schackert G; Vogt-Schaden M; Egerer G; Lamprecht M; Batchelor TT; Schlegel U; Schmidt-Wolf IG;
Ger Med Sci; 2011; 9():Doc11. PubMed ID: 21698087
[TBL] [Abstract][Full Text] [Related]
14. Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy.
Roschewski M; Hodson DJ
Haematologica; 2024 Feb; 109(2):388-400. PubMed ID: 37706315
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
Malfona F; Testi AM; Moleti ML; Petrucci L; Leccisotti L; Martelli M; Di Rocco A
Leuk Lymphoma; 2022 Feb; 63(2):483-486. PubMed ID: 34612154
[No Abstract] [Full Text] [Related]
17. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
del Rio MS; Choquet S; Hoang-Xuan K; Glaisner S; Fourme E; Janvier M; Soussain C
J Neurooncol; 2011 Nov; 105(2):409-14. PubMed ID: 21656329
[TBL] [Abstract][Full Text] [Related]
18. Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
Moore DC; Soni AC; Hu B; Smith ET; Levine J; Moyo TK; Jacobs R; Ghosh N; Park SI
Br J Haematol; 2022 Feb; 196(4):e30-e33. PubMed ID: 34642938
[No Abstract] [Full Text] [Related]
19. Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.
Hatzl S; Posch F; Deutsch A; Beham-Schmid C; Stöger H; Greinix H; Pichler M; Neumeister P; Prochazka KT
Hematol Oncol; 2020 Aug; 38(3):277-283. PubMed ID: 32101329
[TBL] [Abstract][Full Text] [Related]
20. Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma.
Zhang JP; Lee EQ; Nayak L; Doherty L; Kesari S; Muzikansky A; Norden AD; Chen H; Wen PY; Drappatz J
J Neurooncol; 2013 Oct; 115(1):71-7. PubMed ID: 23828279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
